Natco Pharma shares surged 5% to Rs 1,569 after filing an ANDA with the US FDA for a generic cancer drug. The company aims for 180 days of marketing exclusivity.
US markets are nearing record highs, influenced by economic data and trade policies. Tax and spending legislation are under consideration. Donald Trump plans to negotiate
Wall Street faces challenges due to Donald Trump’s unpredictable policies. Macro hedge funds are experiencing their worst start in two decades. Market narratives shift rapidly,
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003